Group 1 - Several private companies, including Zhongjie Automotive and Jiangshun Technology, successfully listed on the A-share market, raising over 45 billion yuan through various financing methods by April 27 [1] - The multi-level capital market in China is actively supporting the development of private enterprises, creating a vibrant and innovative environment for growth [3] - Approximately two-thirds of listed companies on the A-share market are private enterprises, with a significant presence in the ChiNext, Sci-Tech Innovation Board, and Beijing Stock Exchange [4] Group 2 - The private sector is showing resilience and vitality, with a number of leading companies reaching a market value of over 100 billion yuan, contributing to national economic growth and technological innovation [4] - The strategic emerging industries are favored by capital, with private enterprises in information technology and high-end equipment manufacturing accounting for 58% of the total financing [4] - The merger and acquisition market is becoming more active, with over 80 ongoing M&A cases in A-shares, of which more than 60% involve private enterprises [6] Group 3 - The bond market is expanding with various financing tools being introduced to support private enterprises, including the issuance of fixed-income products totaling 35.37 billion yuan in Shenzhen [7] - The Shanghai Stock Exchange has supported over 220 billion yuan in bond and asset-backed securities financing for more than 100 private enterprises in the past year [7] - The People's Bank of China and other regulatory bodies are expected to innovate and expand the issuance of private technology bonds [8] Group 4 - Regulatory bodies are focusing on enhancing the capital market to support technological innovation and the growth of private enterprises, with measures to improve market inclusivity and transparency [9] - In the first quarter of this year, private investment in China increased by 0.4%, with significant growth in manufacturing and infrastructure sectors [9] - Experts suggest further improvements in the multi-level capital market system to facilitate the listing of high-quality private enterprises and optimize the M&A process [10]

裘翔 ｜ 中信证券首席A股策略师 S1010518080002 策略聚焦 ｜ 再次高低切换 在彻底取消所有对华单边关税措施前，中美贸易谈判可能进展有限；国内的政策是托 底和应对式的，4月只是第一波以试验和预防为特征的政策；筹码出清相对彻底且对 业绩不敏感的主题阶段性占优；市场整体情绪位置不算低，科技板块相对医药和消费 更接近冰点，对风偏回升更敏感。配置上，5月关注新技术和产业题材轮动、海外科 技映射链修复以及服务业扩内需政策落地。 风险因素：中美科技、贸易、金融领域摩擦加剧；国内政策力度、实施效果或经济复 苏不及预期；海内外宏观流动性超预期收紧；俄乌、中东地区冲突进一步升级；我国 房地产库存消化不及预期；特朗普政策侧重点超预期。 杨帆｜中信证券 宏观与政策首席分析师 S1010515100001 中信证券｜强化底线思维，充分备足预案：政治局会议学习体会 2025年4月政治局会议指出，虽然一季度经济开局良好，但外部冲击影响加大，下行 风险显著上升；需要"强化底线思维"，对外部压力从最坏处准备，努力争取最好的结 果，因时而动用好政策工具箱，巩固经济与社会稳定。 风险因素：经济增速下行风险；政策力度或效果不及预期； ...

华为与中山七院共建"鲲鹏+昇腾"自主创新平台，将实现医院业务系统、数据库及ICT基础设施的智能 化。创新中心通过AI驱动影像质控优化、远程智能诊疗探索、智慧化病区管理升级及AI辅助临床决策 优化，打造覆盖诊疗全流程的智能化解决方案。 中山七院院长何裕隆强调，智慧医院是公立医院高质量发展的必由之路，此次合作是院企技术整合的典 范，期待通过共建创新中心，实现"优质资源全域共享"。 深圳商报•读创客户端记者 陈姝 4月23日，中山大学附属第七医院（以下简称"中山七院"）与华为技术有限公司（下文简称"华为"）签 署全面合作协议，并与联影医疗技术集团有限公司、深圳市联新移动医疗科技有限公司（以下简称"联 影""联新"）在深圳共同签署三方合作协议，合作共建"中山大学附属第七医院智慧医疗联合创新中 心"（以下简称"创新中心"）。 揭牌仪式（活动主办方供图） 创新中心将采用即将建成的10.0P级医疗人工智能算力中心，通过产学研医深度融合，推动智慧医疗自 主创新，促进医院高质量发展，助力国家实施"健康中国"战略。 在揭牌仪式上，中山七院副院长魏富鑫表示，此次的合作亮点是通过技术赋能，破解临床痛点。此次合 作以打造"三位一体"智 ...

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [12]. Core Viewpoints - The company, United Imaging Healthcare, has emerged as a leading domestic medical imaging equipment manufacturer, breaking the long-standing monopoly of three international companies in the domestic market. It has a significant advantage in research and supply chain capabilities, leading the incremental market and achieving remarkable results. The company is not only focused on the domestic market but is also gradually expanding into overseas markets, benefiting from the ongoing import substitution in the mid-to-high-end medical imaging equipment sector and the release of policy dividends [3][8]. Summary by Relevant Sections Company Overview - Founded in 2011 in Shanghai, United Imaging Healthcare has launched over 120 products, including MRI, CT, XR, PET/CT, PET/MR, RT systems, and life science instruments. The company has consistently ranked first in domestic market share for new additions and has successfully penetrated developed markets such as the US, Japan, and Europe, breaking the long-standing dominance of multinational corporations [8][20]. Market Dynamics - The domestic medical imaging equipment market is experiencing rapid growth, driven by an aging population and increasing healthcare demands. The current domestic equipment ownership per capita is low, with the localization rate of medical imaging equipment (CT, DSA, etc.) ranging from 10% to 50%. The company is well-positioned to capture market share as hospitals increase their investments in medical imaging equipment [9][62][85]. International Expansion - The company has established regional headquarters and R&D centers in the US, Malaysia, UAE, and Poland since 2017. By mid-2024, its products have entered over 70 countries, including the US, Japan, and India. The company employs a "one core, multiple wings" strategy to deepen its presence in North America and Europe while rapidly expanding in India [10][11]. Innovation and R&D - United Imaging Healthcare integrates research, clinical application, and industrial transformation, forming a closed-loop management system from innovation to commercialization. The company collaborates with renowned hospitals and research institutions to leverage complementary strengths in technology and product development [11][32]. Financial Performance - The company forecasts net profits of 1.26 billion, 1.75 billion, and 2.21 billion yuan for 2024, 2025, and 2026, respectively. The current stock price corresponds to P/E ratios of 82X, 59X, and 47X for the respective years [11][12].

中信证券股份有限公司、中国国际金融股份有限公司 （一）联席保荐机构 中信证券股份有限公司、中国国际金融股份有限公司 （二）保荐代表人 关于上海联影医疗科技股份有限公司 2024 年度持续督导工作现场检查报告 上海证券交易所： 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"）、中国国 际金融股份有限公司（以下简称"中金公司"；中信证券和中金公司以下合称"联 席保荐机构"）作为正在履行上海联影医疗科技股份有限公司（以下简称"联影 医疗"、"上市公司"、"公司"）持续督导工作的保荐机构，对公司 2024 年 1 月 1 日至 2024 年 12 月 31 日期间（以下简称"本持续督导期间"）的规范运作情况进 行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （三）现场检查人员 中信证券：焦延延、周阳、刘宇翔 中信证券股份有限公司：焦延延、邵才捷 中国国际金融股份有限公司：张坚柯、张小勇 （四）现场检查时间 2025 年 4 月 17 日 （五）现场检查内容 1 现场检查人员对本持续督导期内发行人公司治理 ...

Core Insights - The Chinese innovative drug market is projected to exceed 1.13 trillion yuan in 2024, with expectations to approach 2.3 trillion yuan by 2030, indicating a high growth trend in the sector [1] - The Hong Kong pharmaceutical ETF (159718) has shown a recent decline of 0.28%, but has increased by 7.16% over the past week [1] - The liquidity of the Hong Kong pharmaceutical ETF is active, with a turnover of 17.21% and a transaction volume of 50.91 million yuan [2] Group 1: Market Performance - As of April 24, 2025, notable stock performances include Xintai Medical (02291) up 13.86%, Ascentage Pharma-B (06855) up 7.36%, and Innovent Biologics (01801) up 4.18% [1] - The Medical Innovation ETF (516820) has a recent turnover of 1.7% and a transaction volume of 28.42 million yuan, with an average daily transaction of 53.10 million yuan over the past month [4] Group 2: Index and Weighting - The CSI Hong Kong Stock Connect Healthcare Index (930965) includes 50 liquid and large-cap healthcare companies, with the top ten stocks accounting for 59.76% of the index [6] - The top ten stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) account for 66.49%, indicating a concentration in leading companies [9] Group 3: Investment Outlook - The manager of Ping An Healthcare Fund, Zhou Sicong, emphasizes that the export of innovative drugs is largely unaffected by U.S. tariff policies due to factors such as high profit margins and the nature of intellectual property [2] - The innovative drug sector is expected to have a promising outlook for Chinese companies, with investors advised not to overreact to short-term policy fluctuations [2]

Core Insights - The healthcare sector is a significant component of global service trade, with the company leading in the independent research and development of core components for high-end medical imaging and radiation therapy products [3][5] - The company has developed over 210 products with complete independent intellectual property rights, achieving international first-class performance standards and facilitating the import substitution of high-end medical equipment [3][5] - The company is actively integrating AI technologies to accelerate the digital transformation of the healthcare service industry, launching a series of intelligent medical models and products that address clinical pain points [6][7] Company Developments - The company has established a vertical innovation system encompassing "complete systems-core components-key components," achieving a leading global self-research ratio for core components [3] - Collaborating with over 200 upstream partners, the company has localized the production and supply of high-precision components, filling domestic gaps in the industry [5] - The company has successfully entered high-end markets in over 85 countries and regions, including the US, Japan, and Italy, with its digital products receiving significant attention [6] Future Directions - The company aims to focus on "high-end, intelligent, and green" directions, striving to create disruptive next-generation digital medical equipment [6] - The upcoming 2025 Beijing Service Trade Fair will showcase the company's innovative products and technologies, enhancing its brand influence and providing opportunities for business connections [7][8]

Investment Rating - The report does not explicitly state an investment rating for the MRI medical imaging industry in China Core Insights - The Chinese MRI medical imaging industry has rapidly developed and is becoming a significant part of the global MRI market, with domestic brands narrowing the gap with international giants through continuous technological innovation [2] - The industry is expected to benefit from supportive policies for domestic medical devices and the implementation of the "Healthy China 2030" initiative, which will enhance overall medical service levels and stimulate MRI equipment demand [2] - The competitive landscape is shifting, with domestic brands expected to dominate the mid-range market due to their cost-effectiveness, while imported brands may introduce economical models to capture market share [3] Summary by Sections Overview of the China MRI Industry - MRI is a non-invasive imaging technology that does not use ionizing radiation, capable of displaying both morphological structures and biochemical information [3][11] - The technology has evolved significantly, becoming one of the fastest-growing imaging techniques in modern medicine [3] Market Size of the China MRI Industry - The market is currently dominated by tertiary hospitals, but secondary hospitals are expected to grow significantly due to policy incentives [44] - The market size is projected to grow from 115.5 billion RMB in 2020 to 243.2 billion RMB by 2029, with a CAGR of 11.0% [46] Industry Chain of the China MRI Industry - The MRI equipment consists of key components such as the magnet system, gradient system, RF system, and computer/image processing system, with the magnet system accounting for over 90% of the cost [56][57] - Domestic brands have made significant progress in developing core components, although some advanced technologies still require further investment [58] Competitive Landscape of the China MRI Industry - The competitive landscape is characterized by a concentration of patents in high-end MRI technologies within Chinese institutions, but commercialization lags behind foreign companies [49] - Domestic MRI companies are encouraged to collaborate with research institutions to convert patent advantages into marketable products [49]

Group 1 - The core viewpoint of the news is that the CSI Medical Index has shown a slight decline recently, reflecting the overall performance of listed companies in the medical and healthcare sector in China [1] - The CSI Medical Index closed at 6285.16 points, with a trading volume of 13.955 billion yuan, down 0.04% [1] - Over the past month, the CSI Medical Index has decreased by 8.83%, while it has seen a slight increase of 0.12% over the last three months, and a year-to-date decline of 4.13% [1] Group 2 - The CSI Medical Index includes companies involved in medical devices, medical services, and medical information technology, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the CSI Medical Index are WuXi AppTec (10.39%), Mindray Medical (9.5%), Aier Eye Hospital (8.04%), United Imaging (7.08%), Aimeike (3.67%), Huatai Medical (3.62%), Kanglong Chemical (3.16%), TigerMed (3.15%), Yuyue Medical (2.82%), and New Industry (2.74%) [1] - The market share of the CSI Medical Index is 57.96% from the Shenzhen Stock Exchange and 42.04% from the Shanghai Stock Exchange [1] - The industry composition of the CSI Medical Index shows that 97.45% is in the healthcare sector, 2.28% in information technology, and 0.27% in consumer goods [1] Group 3 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December [2] - Weight factors are adjusted in accordance with the sample adjustments, which are fixed until the next scheduled adjustment unless a special situation arises [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to the calculation and maintenance guidelines [2]

Core Insights - Chinese high-end medical equipment is gaining global recognition, with companies like United Imaging leading the way in innovation and technology [1][5][6] - The integration of AI in medical devices is enhancing diagnostic accuracy and treatment efficiency, significantly reducing patient wait times for therapies [5][6] - United Imaging has developed over 210 products with complete independent intellectual property rights, including world-first medical devices, achieving international performance standards [6] Group 1: Company Innovations - United Imaging has introduced the world's first integrated CT-linear accelerator, combining diagnostic and therapeutic functions, which reduces patient wait times for initial radiation therapy from half a month to 15 minutes [5] - The company has established a unique vertical innovation system covering complete machines, core components, and key parts, leading to a high self-research ratio in core components globally [5][6] - Recent advancements include the launch of the "YuanZhi" medical model and over ten AI medical applications, marking a shift towards collective intelligence in healthcare [6] Group 2: Market Expansion - United Imaging has successfully entered high-end markets in over 85 countries, including the US, Japan, and Italy, showcasing the global demand for Chinese high-end medical equipment [5][6] - The company emphasizes its commitment to producing world-class innovative products rather than merely replacing low-end medical devices [6] - The upcoming 2025 Service Trade Fair will feature multiple high-end diagnostic and AI products from United Imaging, further promoting high-quality service trade development [7]